Author(s): WONA WERTEL, WIES?AWA BEDNAREK, GRZEGORZ POLAK, JUSTYNA SURÓWKA,MONIKA KOSZ?A, JAN KOTARSK
Ovarian cancer is the fifth most common cancer and the fourth leading cause of cancer deathamong women in Poland. Despite improvements in surgical techniques and advances inchemotherapy, the overall survival rates still remain unacceptably low. Cancer cells developmany mechanisms to avoid detection and killing by activated effector cells of the host im-mune system, reducing effectiveness of standard anticancer treatment. One of the most pro-mising approaches to modify immunological status of ovarian cancer patients and inducea tumor specific immune response is dendritic cell-based immunotherapy. In this paper wereview the published literature on this subject and present perspectives of dendritic cells usein ovarian cancer immunotherapy.